Abrocitinib versus Placebo or Dupilumab for Atopic Dermatitis | Zendy

Thomas Bieber | Zendy; Eric L. Simpson | Zendy; Jonathan I. Silverberg | Zendy; Diamant Thaçi | Zendy; C. Paul | Zendy; Andrew Pink | Zendy; Yoko Kataoka | Zendy; ChiaYu Chu | Zendy; Marco DiBonaventura | Zendy; Ricardo Rojo | Zendy; Jeremias Antinew | Zendy; Ileana A. Ionita | Zendy; Rodney Sinclair | Zendy; Seth Forman | Zendy; Jacek Zdybski | Zendy; Pinaki Biswas | Zendy; Bimal Malhotra | Zendy; Fan Zhang | Zendy; Hernán Valdez | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Abrocitinib versus Placebo or Dupilumab for Atopic Dermatitis

Author(s) -

Thomas Bieber,

Eric L. Simpson,

Jonathan I. Silverberg,

Diamant Thaçi,

C. Paul,

Andrew Pink,

Yoko Kataoka,

ChiaYu Chu,

Marco DiBonaventura,

Ricardo Rojo,

Jeremias Antinew,

Ileana A. Ionita,

Rodney Sinclair,

Seth Forman,

Jacek Zdybski,

Pinaki Biswas,

Bimal Malhotra,

Fan Zhang,

Hernán Valdez

Publication year - 2021

Publication title -

new england journal of medicine

Language(s) - English

Resource type - Journals

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa2019380

Subject(s) - dupilumab , atopic dermatitis , placebo , dermatology , medicine , alternative medicine , pathology

The oral Janus kinase 1 (JAK1) inhibitor abrocitinib, which reduces interleukin-4 and interleukin-13 signaling, is being investigated for the treatment of atopic dermatitis. Data from trials comparing JAK1 inhibitors with monoclonal antibodies, such as dupilumab, that block interleukin-4 receptors are limited.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research